Vistin Pharma ASA (LTS:0RAM)
kr 27.6 0 (0%) Market Cap: 1.18 Bil Enterprise Value: 1.18 Bil PE Ratio: 19.84 PB Ratio: 3.90 GF Score: 72/100

Q3 2023 Vistin Pharma ASA Earnings Call Transcript

Oct 25, 2023 / 06:30AM GMT
Release Date Price: kr24
Operator

Good day, and thank you for standing by. Welcome to Vistin Pharma Quarterly Report for Q3 2023. (Operator Instructions) Please be advised that today's conference is being recorded. I would now like to hand the call over to your first speaker today, Mr. Kjell-Erik Nordby, CEO of the company. Thank you. Please go ahead.

Kjell;Erik Nordby;Leave of Absence
Vistin Pharma ASA - CEO

()

Thank you, and welcome to Vistin Pharma's third quarter reporting. We are happy to present another strong quarter for the company. We achieved all-time high revenue and also EBITDA and sales volume in the third quarter. The revenue and that NOK 120 million, which is a 30% increase compared to last year. The main driver for the increased revenue is that we had more volumes available for sale from second line that we installed in Q1 last year. Year-to-date, the revenue is NOK 328 million compared to NOK 194 million last year, and that is a total of 69% increase sales. EBITDA ended at NOK 27 million compared to negative NOK 3 million in the last -- in Q3

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot